# A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

> **NCT05636306** · PHASE1 · COMPLETED · sponsor: **NoNO Inc.** · enrollment: 83 (actual)

## Conditions studied

- First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke

## Interventions

- **DRUG:** NoNO-42
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05636306
- **Lead sponsor:** NoNO Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-22
- **Primary completion:** 2023-10-05
- **Final completion:** 2023-10-05
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05636306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05636306, "A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05636306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*